Skip to main content

Table 3 Distribution of genotypes of the investigated SNPs

From: Insulin-like growth factor 1 receptor expression and IGF1R 3129G > T polymorphism are associated with response to neoadjuvant chemotherapy in breast cancer patients: results from the NEOZOTAC trial (BOOG 2010-01)

SNP Allele N = 184 (%) HWE χ2 P value Call rate (%)
rs10735380 AA 110 (54.3) 2.1 0.144 94
IGF1 AG 68 (37.0)    
  GG 5 (2.7)    
  NE 11 (6.0)    
rs1520220 CC 115 (62.5) 4.4 0.040a 94
IGF1 CG 46 k    
  GG 11 (6.0)    
  NE 12 (6.5)    
rs6220 AA 91 (49.5) 3.3 0.068 89
IGF1 AG 56 (30.4)    
  GG 17 (9.2)    
  NE 20 (10.9)    
rs2946834b GG 82 (44.6) 10.1 0.001a 88
IGF1 GA 53 (28.8)    
  AA 26 (14.1)    
  NE 23 (12.5)    
rs2270628 CC 105 (57.1) 2.8 0.096 87
IGFBP3 CT 45 (24.5)    
  TT 10 (5.4)    
  NE 24 (13.0)    
rs2854746 GG 59 (32.1) 1.9 0.170 90
IGFBP3 GC 72 (39.1)    
  CC 34 (18.5)    
  NE 19 (10.3)    
rs4320932 TT 111 (60.3) 0.04 0.843 96
IGF2 TC 57 (31)    
  CC 8 (4.3)    
  NE 8 (4.3)    
rs2016347 GG 48 (26.1) 1.8 0.185 96
IGF1R GT 96 (52.2)    
  TT 32 (17.4)    
  NE 8 (4.3)    
  1. aNot in HWE
  2. bSNP excluded from analyses because the SNP is significantly deviated from HWE after Bonferroni correction
  3. HWE Hardy–Weinberg equilibrium, IGF insulin-like growth factor, IGFBP3 insulin-like growth factor binding protein 3, IGF1R insulin-like growth factor-1 receptor, NE Not evaluable (despite attempt to genotype), SNP single nucleotide polymorphism